Thymosin Alpha-1 5 mg
A thymic peptide investigated in immune-system research.
CAD $80.00 / vial
Vial amount
The specifics, clearly listed.
Product details
Product reference: MRD-0162 Listed amount per vial: 5 mg Sales unit: 1 vial
Read the research in context.
A thymic peptide investigated in immune-system research.
- The efficacy and safety of thymosin alpha 1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial. BMJ, 2025. — source Publisher indexed conclusion and PubMed indexed abstract; full text not reviewed (direct BMJ access returned 403).
- Related indexed item with the same trial title (role/content to be verified before final publication). — source Indexed record located; not silently ignored and not yet appraised.
Access levels: each citation records how much of the source was read. Published findings address the studied material, not this supplied product.
What this doesn’t establish: Thymosin alpha 1 must be kept distinct from thymosin beta 4/TB-500. Full trial text, a related indexed item with the same title, conflicts and current Canadian authorization status remain to be reviewed. Clinical use elsewhere does not infer approved Canadian status.
Product documents
No verified report is available here for this item. Ask about documentation for Thymosin Alpha-1, product reference MRD-0162.
Before you decide.
Separate research about the compound from evidence about the supplied product.
Which vial amount is shown?
This listing shows 5 mg per vial.
Does the study verify this vial?
No. Research on a compound does not establish the identity, quality, safety or effectiveness of a product sold under that name.
What should I check in a report?
Check the sample identity, batch reference, issuer, date, test methods and results. A report applies to the identified sample and tests.
What information should I request?
Ask about the exact product identity, form, specification, handling requirements and relevant batch documents before deciding.